Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Lilamand

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|May 19, 2023
Response to the Comment on "Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer's Disease Diagnosis in Cognitively Impaired Patients"Matthieu Lilamand, Elodie Bouaziz-Amar, Julien Dumurgier, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 28, 2022
Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer's Disease Diagnosis in Cognitively Impaired PatientsMatthieu Lilamand, Elodie Bouaziz-Amar, Julien Dumurgier, et al.
Clinical Chemistry and Laboratory Medicine|August 30, 2025
Cerebrospinal fluid leptin in Alzheimer's disease: relationship to plasma levels and to cerebrospinal amyloidElodie Bouaziz-Amar, Jeanne Neez, Fidaa Ibrahim, et al.
International Journal of Molecular Sciences|November 11, 2022
Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical PracticeMatthieu Lilamand, Josué Clery, Agathe Vrillon, et al.
Alzheimer'S Research & Therapy|March 30, 2019
CSF level of β-amyloid peptide predicts mortality in Alzheimer's diseaseAdla Boumenir, Emmanuel Cognat, Severine Sabia, et al.
Journal of the American Medical Directors Association|September 28, 2016
Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for CliniciansNatalia Del Campo, Matteo Cesari, Marco Canevelli, et al.
Metabolic Brain Disease|June 26, 2026
Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinicLouise Sindzingre, Théodore Decaix, Karl Gotze, et al.
Neurobiology of Disease|December 3, 2022
Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life studyKarl Götze, Agathe Vrillon, Elodie Bouaziz-Amar, et al.
Ebiomedicine|April 16, 2025
Dissection of blood-brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disordersAgathe Vrillon, Nicholas J Ashton, Elodie Bouaziz-Amar, et al.
Journal of Neurology|March 24, 2026
Eligibility for lecanemab treatment in a French memory clinic settingAgathe Vrillon, Karl Götze, Julien Dumurgier, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|May 19, 2023
Response to the Comment on "Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer's Disease Diagnosis in Cognitively Impaired Patients"Matthieu Lilamand, Elodie Bouaziz-Amar, Julien Dumurgier, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|November 28, 2022
Plasma Leptin Is Associated With Amyloid CSF Biomarkers and Alzheimer's Disease Diagnosis in Cognitively Impaired PatientsMatthieu Lilamand, Elodie Bouaziz-Amar, Julien Dumurgier, et al.
Clinical Chemistry and Laboratory Medicine|August 30, 2025
Cerebrospinal fluid leptin in Alzheimer's disease: relationship to plasma levels and to cerebrospinal amyloidElodie Bouaziz-Amar, Jeanne Neez, Fidaa Ibrahim, et al.
International Journal of Molecular Sciences|November 11, 2022
Cerebrospinal Fluid Alpha-Synuclein Improves the Differentiation between Dementia with Lewy Bodies and Alzheimer's Disease in Clinical PracticeMatthieu Lilamand, Josué Clery, Agathe Vrillon, et al.
Alzheimer'S Research & Therapy|March 30, 2019
CSF level of β-amyloid peptide predicts mortality in Alzheimer's diseaseAdla Boumenir, Emmanuel Cognat, Severine Sabia, et al.
Journal of the American Medical Directors Association|September 28, 2016
Refining Mild-to-Moderate Alzheimer Disease Screening: A Tool for CliniciansNatalia Del Campo, Matteo Cesari, Marco Canevelli, et al.
Metabolic Brain Disease|June 26, 2026
Plasma and CSF adiponectin levels in biomarker-confirmed Alzheimer's disease: A cross-sectional study in a tertiary memory clinicLouise Sindzingre, Théodore Decaix, Karl Gotze, et al.
Neurobiology of Disease|December 3, 2022
Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life studyKarl Götze, Agathe Vrillon, Elodie Bouaziz-Amar, et al.
Ebiomedicine|April 16, 2025
Dissection of blood-brain barrier dysfunction through CSF PDGFRβ and amyloid, tau, neuroinflammation, and synaptic CSF biomarkers in neurodegenerative disordersAgathe Vrillon, Nicholas J Ashton, Elodie Bouaziz-Amar, et al.
Journal of Neurology|March 24, 2026
Eligibility for lecanemab treatment in a French memory clinic settingAgathe Vrillon, Karl Götze, Julien Dumurgier, et al.
Pageof 7